Interesting conundrum - if we have tens of thousands of off label prescriptions for Alzheimers, can that data be compiled and used to support the double blind study and/or compel the FDA to approve compassionate use or approve early?
Are there any other examples of an orphan drug approval used to treat a much larger indication off label in high volume?
News 
Market Data 
Discover 
